Novel osteopontin derived chemotactic peptides and methods of use
AssigneeChildren's Medical Center Corporation
InventorSamy Ashkar
Life of this patent
Estimating the term…
Abstract
Novel osteopontin derived chemotactic peptides are described. The peptides (or antagonists thereof) are useful in treating conditions or diseases associated with chemotaxis.
Claims33
A purified osteopontin derived chemotactic peptide.
A purified osteopontin derived peptide having chemotactic activity.
A purified osteopontin derived chemotactic peptide comprising the amino acid sequence LVLDPK (SEQ ID NO:1).
A purified osteopontin derived peptide comprising the amino acid sequence LVLDPK (SEQ ID NO:1) and having chemotactic activity.
A purified osteopontin derived chemotactic peptide comprising the amino acid sequence VLDPK (SEQ ID NO:7).
A purified osteopontin derived peptide comprising the amino acid sequence VLDPK (SEQ ID NO:7) and having chemotactic activity.
An isolated nucleic acid encoding an osteopontin derived peptide having chemotactic activity.
A purified osteopontin derived chemotactic peptide comprising the amino acid sequence LVLDPK (SEQ ID NO:1) wherein said peptide is no more than about 60 amino acids in length.
A purified osteopontin derived chemotactic peptide comprising a sequence of the formula n-R1—R2—R3—R4—R5—R6—R7—R8-c, wherein
- R1 is 0, 1, 3, 5, 10, 15, 20, 25, or 27 amino acids long;
- R2 is Leu, Val, Met or absent;
- R3 is Val, Leu, Ile or Met;
- R4 is Leu, Val, Pro or Ile;
- R5 is aspartic acid or any acidic amino acid;
- R6 is Pro or Ser;
- R7 is Lys, Arg, Met or Ile;
- R8 is 0, 1, 3, 5, 10, 15, 20, 25 or 27 amino acids long;
- wherein c indicates the carboxy terminal direction of the peptide and n indicates the amino terminal direction of the peptide.
A therapeutic composition comprising an osteopontin derived chemotactic peptide and a pharmaceutically-acceptable carrier or diluent.
A method for modulating tumor invasion in a subject, comprising administering to a subject a therapeutically effective amount of an antagonist of an osteopontin derived chemotactic peptide such that tumor invasion is modulated.
A method for promoting wound healing in a subject, comprising administering to a subject a therapeutically effective amount of a composition comprising an osteopontin derived chemotactic peptide and a a pharmaceutically-acceptable carrier or diluent such that wound healing is promoted.
A method for modulating tumor metastasis formation, comprising administering to a subject a therapeutically effective amount of an antibody specifically reactive with an osteopontin derived chemotactic peptide such that tumor metastasis formation is modulated.
A method for promoting cell migration to a target site, comprising administering to a cell a therapeutically effective amount of an osteopontin derived chemotactic peptide such that migration of said cell to said target site is promoted.
A method for modulating cellular chemotaxis, comprising administering to a cell a therapeutically effective amount of an osteopontin derived chemotactic peptide such that modulation of cellular chemotaxis occurs.
In a prosthetic device, the improvement comprising, the incorporation of a therapeutically effective amount of an osteopontin derived chemotactic peptide in said prosthetic device.
A method for treating the formation of atherosclerotic plaques, comprising administering to a subject a therapeutically effective amount of an osteopontin derived chemotactic peptide such that formation of artherosclerotic plaques is prevented.
A method for treating an angiogenic-associated disease, comprising administering to a subject a therapeutically effective amount of an antibody specifically reactive with an osteopontin derived chemotactic peptide such that treatment of angiogenic-associated disease occurs.
A method of inducing either in vitro or in vivo chemotaxis of a cell, comprising administering to a cell an osteopontin derived chemotactic peptide in an amount effective to induce chemotaxis.
An antibody specifically reactive with an osteopontin derived chemotactic peptide.
Dependencies are inferred from the claim text.